Asset profile
Ampreloxetine (TD-9855)
Small molecule
Evidence outlook · lead readout
SEQUOIA (NCT03750552) · Neurogenic Orthostatic Hypotension
The lead readout missed its primary endpoint. The grade and rationale below record what the trial was designed to show and what it found.
SEQUOIA (NCT03750552): The study was randomized, quadruple-blind, placebo-controlled, and included 195 participants. Its primary clinical symptom endpoint was not met: the change in dizziness/lightheadedness score did not differ significantly from placebo (p=0.574), so the results provide well-controlled but unclear evidence of benefit.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
1 competitor in this universe: 0 direct rivals (same mechanism and indication), 1 same-class, 0 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Ampreloxetine (TD-9855): this drug | Phase 3 | Small molecule | norepinephrine transporter | ||
| Reboxetine | Phase 3 | Small molecule | norepinephrine transporter |
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.